Non-Small Cell Lung Cancer
Dr. Merritt shares new thoracic surgery research insights for patient selection in sublobar resection for early-stage NSCLC.
The study aims to confirm safety and efficacy findings from the phase 2 QUILT 3.055 trial.
The study is evaluating a prophylactic dermatologic regimen in patients receiving amivantamab plus lazertinib.
The CHMP positive opinion is supported by results from the phase 3 PALOMA-3 study.
Dr. Seder discusses the real-world study he presented at STS 2025, which addressed key questions about long-term outcomes.
Pending discussions with the FDA, officials say there are plans to submit for regulatory approval in the second half of 2025.
Clinical Considerations Surrounding Sublobar Resection in NSCLC: Dr. Merritt Discusses Recent Review
Robert E. Merritt, MD, MBA, FACS, shares insights on his systematic review of sublobar resection and lobectomy. 
Mara B. Antonoff, MD, FACS, shares key considerations and developments in surgery for stage IV lung cancer.
However, the study findings presented at STS 2025 suggest that segmentectomy may be a “viable alternative” to lobectomy.
Despite decades of decline, "lung cancer continues to dwarf other cancers in the number of deaths," officials said.
Advertisement
Expert Interviews on Lung Cancer
Advertisement
Advertisement
Section Editor
Stephen V. Liu, MDThoracic Medical Oncologist | Georgetown University
Advertisement
Latest Lung Cancer News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.